Prognostic significance of syndecan-1 expression in human endometrial cancer

Hasengaowa, J. Kodama, T. Kusumoto, Y. Shinyo, N. Seki, Y. Hiramatsu

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans. The aim of this study was to investigate syndecan-1 expression in endometrial cancers. Patients and methods: We investigated the expression of the syndecan-1 core protein by immunohistochemistry in 109 endometrial cancers, and analyzed correlation with various clinicopathological features, including patient outcome. Results: Epithelial syndecan-1 expression was significantly lower in advanced stage, high grade, deep myometrial invasion, cervical involvement, lymph node metastasis, lymph vascular space involvement and positive peritoneal cytology. Stromal syndecan-1 expression was significantly higher in high-grade tumors. The disease-free and overall survival rates of patients exhibiting both low epithelial and high stromal syndecan-1 expression was poor. Multivariate analysis showed that high stromal syndecan-1 expression was an independent prognostic factor for both disease-free and overall survival. Low epithelial syndecan-1 expression was a prognostic factor only in the univariate analysis. Conclusions: Loss of epithelial syndecan-1 and induction of stromal syndecan-1 expression may be associated with tumor progression. Stromal syndecan-1 expression can serve as an indicator of poor prognosis in patients with endometrial cancer.

Original languageEnglish
Pages (from-to)1109-1115
Number of pages7
JournalAnnals of Oncology
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Syndecan-1
Endometrial Neoplasms
Disease-Free Survival
Heparitin Sulfate
Lymph
Glycosaminoglycans
Extracellular Matrix
Blood Vessels
Cell Biology
Neoplasms

Keywords

  • Endometrial cancer
  • Prognosis
  • Syndecan-1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hasengaowa, Kodama, J., Kusumoto, T., Shinyo, Y., Seki, N., & Hiramatsu, Y. (2005). Prognostic significance of syndecan-1 expression in human endometrial cancer. Annals of Oncology, 16(7), 1109-1115. https://doi.org/10.1093/annonc/mdi224

Prognostic significance of syndecan-1 expression in human endometrial cancer. / Hasengaowa; Kodama, J.; Kusumoto, T.; Shinyo, Y.; Seki, N.; Hiramatsu, Y.

In: Annals of Oncology, Vol. 16, No. 7, 07.2005, p. 1109-1115.

Research output: Contribution to journalArticle

Hasengaowa, Kodama, J, Kusumoto, T, Shinyo, Y, Seki, N & Hiramatsu, Y 2005, 'Prognostic significance of syndecan-1 expression in human endometrial cancer', Annals of Oncology, vol. 16, no. 7, pp. 1109-1115. https://doi.org/10.1093/annonc/mdi224
Hasengaowa, Kodama J, Kusumoto T, Shinyo Y, Seki N, Hiramatsu Y. Prognostic significance of syndecan-1 expression in human endometrial cancer. Annals of Oncology. 2005 Jul;16(7):1109-1115. https://doi.org/10.1093/annonc/mdi224
Hasengaowa ; Kodama, J. ; Kusumoto, T. ; Shinyo, Y. ; Seki, N. ; Hiramatsu, Y. / Prognostic significance of syndecan-1 expression in human endometrial cancer. In: Annals of Oncology. 2005 ; Vol. 16, No. 7. pp. 1109-1115.
@article{9107d3d5eaf94408892fd8e594d0ebb7,
title = "Prognostic significance of syndecan-1 expression in human endometrial cancer",
abstract = "Background: Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans. The aim of this study was to investigate syndecan-1 expression in endometrial cancers. Patients and methods: We investigated the expression of the syndecan-1 core protein by immunohistochemistry in 109 endometrial cancers, and analyzed correlation with various clinicopathological features, including patient outcome. Results: Epithelial syndecan-1 expression was significantly lower in advanced stage, high grade, deep myometrial invasion, cervical involvement, lymph node metastasis, lymph vascular space involvement and positive peritoneal cytology. Stromal syndecan-1 expression was significantly higher in high-grade tumors. The disease-free and overall survival rates of patients exhibiting both low epithelial and high stromal syndecan-1 expression was poor. Multivariate analysis showed that high stromal syndecan-1 expression was an independent prognostic factor for both disease-free and overall survival. Low epithelial syndecan-1 expression was a prognostic factor only in the univariate analysis. Conclusions: Loss of epithelial syndecan-1 and induction of stromal syndecan-1 expression may be associated with tumor progression. Stromal syndecan-1 expression can serve as an indicator of poor prognosis in patients with endometrial cancer.",
keywords = "Endometrial cancer, Prognosis, Syndecan-1",
author = "Hasengaowa and J. Kodama and T. Kusumoto and Y. Shinyo and N. Seki and Y. Hiramatsu",
year = "2005",
month = "7",
doi = "10.1093/annonc/mdi224",
language = "English",
volume = "16",
pages = "1109--1115",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Prognostic significance of syndecan-1 expression in human endometrial cancer

AU - Hasengaowa,

AU - Kodama, J.

AU - Kusumoto, T.

AU - Shinyo, Y.

AU - Seki, N.

AU - Hiramatsu, Y.

PY - 2005/7

Y1 - 2005/7

N2 - Background: Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans. The aim of this study was to investigate syndecan-1 expression in endometrial cancers. Patients and methods: We investigated the expression of the syndecan-1 core protein by immunohistochemistry in 109 endometrial cancers, and analyzed correlation with various clinicopathological features, including patient outcome. Results: Epithelial syndecan-1 expression was significantly lower in advanced stage, high grade, deep myometrial invasion, cervical involvement, lymph node metastasis, lymph vascular space involvement and positive peritoneal cytology. Stromal syndecan-1 expression was significantly higher in high-grade tumors. The disease-free and overall survival rates of patients exhibiting both low epithelial and high stromal syndecan-1 expression was poor. Multivariate analysis showed that high stromal syndecan-1 expression was an independent prognostic factor for both disease-free and overall survival. Low epithelial syndecan-1 expression was a prognostic factor only in the univariate analysis. Conclusions: Loss of epithelial syndecan-1 and induction of stromal syndecan-1 expression may be associated with tumor progression. Stromal syndecan-1 expression can serve as an indicator of poor prognosis in patients with endometrial cancer.

AB - Background: Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans. The aim of this study was to investigate syndecan-1 expression in endometrial cancers. Patients and methods: We investigated the expression of the syndecan-1 core protein by immunohistochemistry in 109 endometrial cancers, and analyzed correlation with various clinicopathological features, including patient outcome. Results: Epithelial syndecan-1 expression was significantly lower in advanced stage, high grade, deep myometrial invasion, cervical involvement, lymph node metastasis, lymph vascular space involvement and positive peritoneal cytology. Stromal syndecan-1 expression was significantly higher in high-grade tumors. The disease-free and overall survival rates of patients exhibiting both low epithelial and high stromal syndecan-1 expression was poor. Multivariate analysis showed that high stromal syndecan-1 expression was an independent prognostic factor for both disease-free and overall survival. Low epithelial syndecan-1 expression was a prognostic factor only in the univariate analysis. Conclusions: Loss of epithelial syndecan-1 and induction of stromal syndecan-1 expression may be associated with tumor progression. Stromal syndecan-1 expression can serve as an indicator of poor prognosis in patients with endometrial cancer.

KW - Endometrial cancer

KW - Prognosis

KW - Syndecan-1

UR - http://www.scopus.com/inward/record.url?scp=25444495294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444495294&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi224

DO - 10.1093/annonc/mdi224

M3 - Article

C2 - 15851381

AN - SCOPUS:25444495294

VL - 16

SP - 1109

EP - 1115

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -